346 related articles for article (PubMed ID: 17544970)
1. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
Adams LA; Angulo P
Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive assessment of fibrosis and steatosis in NASH and ASH.
Angulo P
Gastroenterol Clin Biol; 2009; 33(10-11):940-8. PubMed ID: 19800187
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
Suzuki A; Angulo P; Lymp J; Li D; Satomura S; Lindor K
Liver Int; 2005 Aug; 25(4):779-86. PubMed ID: 15998429
[TBL] [Abstract][Full Text] [Related]
4. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
Adams LA; George J; Bugianesi E; Rossi E; De Boer WB; van der Poorten D; Ching HL; Bulsara M; Jeffrey GP
J Gastroenterol Hepatol; 2011 Oct; 26(10):1536-43. PubMed ID: 21950746
[TBL] [Abstract][Full Text] [Related]
5. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
Pagadala M; Zein CO; McCullough AJ
Clin Liver Dis; 2009 Nov; 13(4):591-606. PubMed ID: 19818307
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease.
Nobili V; Alisi A; Torre G; De Vito R; Pietrobattista A; Morino G; De Ville De Goyet J; Bedogni G; Pinzani M
Transl Res; 2010 Oct; 156(4):229-34. PubMed ID: 20875899
[TBL] [Abstract][Full Text] [Related]
7. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease.
Calès P; Boursier J; Chaigneau J; Lainé F; Sandrini J; Michalak S; Hubert I; Dib N; Oberti F; Bertrais S; Hunault G; Cavaro-Ménard C; Gallois Y; Deugnier Y; Rousselet MC
Liver Int; 2010 Oct; 30(9):1346-54. PubMed ID: 20666992
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
[TBL] [Abstract][Full Text] [Related]
10. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
[TBL] [Abstract][Full Text] [Related]
11. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
[TBL] [Abstract][Full Text] [Related]
12. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients.
Manousou P; Kalambokis G; Grillo F; Watkins J; Xirouchakis E; Pleguezuelo M; Leandro G; Arvaniti V; Germani G; Patch D; Calvaruso V; Mikhailidis DP; Dhillon AP; Burroughs AK
Liver Int; 2011 May; 31(5):730-9. PubMed ID: 21457446
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology.
Colak Y; Senates E; Ozturk O; Yilmaz Y; Zemheri E; Yilmaz Enc F; Ulasoglu C; Aksaray S; Bozbeyoglu SG; Kiziltas S; Kurdas OO; Tuncer I
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):255-61. PubMed ID: 22157234
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease.
Vizzutti F; Arena U; Nobili V; Tarquini R; Trappoliere M; Laffi G; Marra F; Pinzani M
Ann Hepatol; 2009; 8(2):89-94. PubMed ID: 19502649
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon.
Charlton M
Am J Gastroenterol; 2007 Feb; 102(2):409-11. PubMed ID: 17311653
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
17. Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
[TBL] [Abstract][Full Text] [Related]
18. Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach.
Valenti L; Dongiovanni P
Transl Res; 2010 Oct; 156(4):226-8. PubMed ID: 20875898
[TBL] [Abstract][Full Text] [Related]
19. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
[TBL] [Abstract][Full Text] [Related]
20. Histological assessment of non-alcoholic fatty liver disease.
Hübscher SG
Histopathology; 2006 Nov; 49(5):450-65. PubMed ID: 17064291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
